ESPERION THERAPEUTICS INC. - COMMON STOCK

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

29 Apr 2022 17:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference

29 Apr 2022 10:00:00 By Nasdaq GlobeNewswire

Esperion Announces the Appointment of Stephen Rocamboli to its Board of Directors

28 Apr 2022 16:00:00 By Nasdaq GlobeNewswire

Esperion Supports Collaborative Study with an Integrated and Learning Health Care Delivery System in Northern California to Study the Effects of NEXLIZET® (bempedoic acid and ezetimibe) in Reducing LDL-Cholesterol Following a Recent Acute Coronary Syndrome Event

25 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Esperion to Report First Quarter 2022 Financial Results May 3, 2022

19 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Esperion Announces Publication of Phase 3 Data for Bempedoic Acid in the Journal of Clinical Lipidology

13 Apr 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion Announces Two NEXLETOL® (bempedoic acid) Data Presentations at the American College of Cardiology’s 71st Annual Scientific Session & Expo

03 Apr 2022 12:00:00 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming 21st Annual Needham Virtual Healthcare Conference

29 Mar 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Virtual Cowen 42nd Annual Healthcare Conference

24 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update

22 Feb 2022 07:00:02 By Nasdaq GlobeNewswire

Esperion to Report Fourth Quarter and Full Year 2021 Financial Results February 22, 2022

08 Feb 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

28 Jan 2022 17:00:00 By Nasdaq GlobeNewswire

Esperion Provides Preliminary Fourth Quarter 2021 Financial Results and CLEAR Outcomes Program Update

11 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion to Participate in Upcoming Virtual J.P. Morgan 40th Annual Healthcare Conference

06 Jan 2022 08:00:01 By Nasdaq GlobeNewswire

Esperion Appoints Benjamin O. Looker as General Counsel

04 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Esperion Announces Closing of $225 Million Public Offering

07 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Esperion Announces Pricing of $225 Million Public Offering

02 Dec 2021 23:40:00 By Nasdaq GlobeNewswire

Esperion Announces Proposed Public Offering

02 Dec 2021 17:00:00 By Nasdaq GlobeNewswire

Esperion Presents Important New Science Highlighting Potential Benefits of NEXLETOL® (bempedoic acid) Tablets at American Heart Association Scientific Sessions 2021

12 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Esperion Reports Third Quarter 2021 Financial Results and Provides Company Update

02 Nov 2021 07:00:01 By Nasdaq GlobeNewswire